Anti-viral compounds

US10028937B2 · kind B2 · utility

Assignee

• Abb Vie Inc. · US

Inventors

• Mary E. Bellizzi · North Chicago, US
• David A. Betebenner · Lawrenceville, US
• Jean C. Califano · Whitefish Bay, US
• William A. Carroll · Evanston, US
• Daniel D. Caspi · Evanston, US
• David A. DeGoey · Salem, US
• Pamela L. Donner · Mundelein, US
• Charles A. Flentge · Salem, US
• Yi Gao · Vernon Hills, US
• Charles W. Hutchins · Libertyville, US
• Douglas K. Hutchinson · Antioch, US
• Tammie K. Jinkerson · Pleasant Prairie, US
• Warren M. Kati · Gurnee, US
• Ryan G. Keddy · Beach Park, US
• Allan C. Krueger · Gurnee, US
• Wenke Li · Gurnee, US
• Dachun Liu · Vernon Hills, US
• Clarence J. Maring · Libertyville, US
• Mark A. Matulenko · Libertyville, US
• Christopher E. Motter · Oak Creek, US
• Lissa T. Nelson · Highland Park, US
• Sachin V. Patel · Round Lake, US
• John K. Pratt · Kenosha, US
• John T. Randolph · Libertyville, US
• Todd W. Rockway · Gurnee, US
• Kathy Sarris · Mundelein, US
• Michael D. Tufano · Chicago, US
• Seble H. Wagaw · Lake Bluff, US
• Rolf Wagner · Antioch, US
• Kevin R. Woller · Antioch, US

Key dates

• Filing date: Feb 16, 2017
• Grant date: Jul 24, 2018
• Expiry date: Feb 16, 2037

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02P20/582
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.